Search results
Results from the WOW.Com Content Network
The COVID-19 mRNA vaccines from Moderna and Pfizer–BioNTech had short-term efficacy rates of over 90 percent against the original SARS-CoV-2 virus. Prior to mRNA, drug trials on pathogens other than COVID-19 were not effective and had to be abandoned in the early phases of trials. The reason for the efficacy of the new mRNA vaccines is not clear.
When the SARS-CoV-2 virus emerged in China in 2019, BioNTech had already used mRNA technology to design a vaccine against the Zika virus, which had infected hundreds of thousands of pregnant women ...
Two pioneering scientists who created the technology behind life-saving Covid-19 vaccines have won the Nobel Prize in medicine or physiology.
The first mRNA-based vaccines received restricted authorization and were rolled out across the world during the COVID-19 pandemic by Pfizer–BioNTech COVID-19 vaccine and Moderna, for example. [55] The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for the development of effective mRNA vaccines ...
Hoerr did experimental research on the stabilization of messenger ribonucleic acid (mRNA). In 1999, he received his PhD from Günther Jung, Institute of Organic Chemistry, in cooperation with Hans-Georg Rammensee, Institute of Immunology and Cell Biology (both: University of Tübingen) on the topic of RNA vaccines for the induction of specific cytotoxic T lymphocytes (CTL) and antibodies.
Although the quality and quantity of antibody production by a potential vaccine is intended to neutralize the COVID‑19 infection, a vaccine may have an unintended opposite effect by causing antibody-dependent disease enhancement (ADE), which increases the virus attachment to its target cells and might trigger a cytokine storm if a vaccinated ...
Strands of mRNA, or messenger RNA, are tiny snippets of genetic code that tell the body how to build proteins, essential building blocks of every cell in the body. The idea behind an mRNA vaccine ...
Since mRNA vaccines can be easily designed to target any antigen, the team could use the mutation fingerprint of cancers for engineering mRNA-based personalized neo-antigen vaccines. This application offers the possibility of targeting each patient's tumor mutations with an individually tailored mRNA vaccine of unique composition that is ...